Program
sacubitril
Also written as “sacubitril/valsartan”, “Experimental: Sacubitril/Allisartan and Amlodipine Group” and “AHU377”.
Its studies are mostly in Heart Failure · Essential Hypertension · Chagas Disease · Myocardial Infarction · Isolated Systolic Hypertension, led by 4 companies.
Drug pageSacubitril: every studyAll 48 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novartis | 80 open or running | phase 4since Jul 10, 2019 | Oct 5, 2007 | none ahead |
| Shenzhen Salubris Pharmaceuticalsits history only | 20 open or running | phase 3since Jul 9, 2026 | Jul 9, 2026 | none ahead |
| Viatrisits history only | 22 open or running | phase 1since Jan 25, 2024 | Jan 25, 2024 | none ahead |
| Dr. Reddy's Laboratoriesits history only | 11 open or running | phase 1since Dec 12, 2023 | Dec 12, 2023 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of Novartis only; the figures above count every company.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 5, 2007First study: phase 2 study in HypertensionFirst studyNCT00549770 · 1,334 enrolled · United States, Argentina, Canada and more
- Jan 20, 2011Phase 2 study in Isolated Systolic HypertensionNCT01281306 · 910 enrolled · United States, Argentina, Canada and more
- Feb 23, 2017Phase 3 study in Cardiovascular DiseasesNCT03066804 · 2,572 enrolled · United States, Argentina, Austria and more
- Dec 20, 2018Phase 3 study in Heart FailureNCT03785405 · 216 enrolled · United States, Argentina, Austria and more
- Jun 13, 2019Phase 3 study in Heart Failure With Preserved Ejection Fraction (HFpEF)NCT03988634 · 467 enrolled · United States, Canada
- Jul 10, 2019Phase 4 study in Chagas DiseaseNCT04023227 · 922 enrolled · Argentina, Brazil, Colombia and more
- Nov 4, 2020Phase 3 study in Post Myocardial InfarctionNCT04637555
- Nov 13, 2023Phase 3 study in Heart FailureNCT06149104 · 8 enrolled · Japan
TargetBeta
“A neprilysn (NEP) inhibitor prodrug with natriuretic activity”NCIt, by rule
“Neprilysin inhibitor”ChEMBL 37, by rule
Studies
All 8 Novartis leads, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT06149104Heart Failure · Japan | 3 | Completed | Aug 14, 2024 | 8 |
| NCT04637555Post Myocardial Infarction | 3 | Withdrawn | Jun 1, 2023 | 0 |
| NCT04023227Chagas Disease · Argentina, Brazil, Colombia and more | 4 | Completed | Mar 16, 2025 | 922 |
| NCT03988634Heart Failure With Preserved Ejection Fraction (HFpEF) · United States, Canada | 3 | Completed | Dec 14, 2022 | 467 |
| NCT03785405Heart Failure · United States, Argentina, Austria and more | 3 | Completed | Dec 29, 2023 | 216 |
| NCT03066804Cardiovascular Diseases · United States, Argentina, Austria and more | 3 | Completed | Oct 28, 2019 | 2,572 |
| NCT01281306Isolated Systolic Hypertension · United States, Argentina, Canada and more | 2 | Completed | Dec 2011 | 910 |
| NCT00549770Hypertension · United States, Argentina, Canada and more | 2 | Completed | Jul 2008 | 1,334 |
How it is read
Names in the registry
- “sacubitril/valsartan”, 5 entries
- “Experimental: Sacubitril/Allisartan and Amlodipine Group”, 2 entries
- “AHU377”, 2 entries
- “Sacubitril/valsartan”, 1 entry
- “Sacubitril and Valsartan Tablets 49mg/51mg”, 1 entry
Conditions, from the studies’ own filings
- Heart Failure, 5 studies
- Essential Hypertension, 2 studies
- Chagas Disease, 1 study
- Myocardial Infarction, 1 study
- Isolated Systolic Hypertension, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.